Carboplatin in Castration-resistant Prostate Cancer
Open label, non-randomised phase II clinical pilot study
Prostatic Neoplasm
DRUG: Carboplatin
Response, Soft tissue or PSA Response, Time Frame: Up to the end of the treatment phase (ie, approximately 6 months
Rate of PSA declines of â‰¥30%, PSA, Time Frame: At 12 weeks and up to the end of the treatment phase (ie, approximately 6 months)|OS, Overall survival (OS) form start of Carboplatin, Time Frame: livelong follow-up|rPFS, Radiological progression-free survival (rPFS) from start of carboplatin, Time Frame: Up to the end of the treatment phase (ie, approximately 6 months|PSA, Time to PSA progression, on studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months|Safety as per CTC AEv4.03, Number of patients with adverse events, on studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months|Disease control rate, Disease control rate at 12 and 24 weeks (defined as SD, PR, CR, see response criteria, On studyTime Frame: Up to the end of the treatment phase (ie, approximately 6 months|PTEN loss, Evaluation of PTEN loss by FISH (Frequency and correlation with IHC), Pre-study biopsy sample
Pilot Study of weekly Carboplatin in Patients with Advanced Metastatic Castration-Resistant Prostate Cancer (CRPC) and DNA repair defects